Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

May 8, 2022

Study Completion Date

May 24, 2022

Conditions
Drug Drug Interaction
Interventions
DRUG

Givinostat

"Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension~On days 1 and 13 givinostat was administered in the morning, following an overnight fasting of at least 8 hours and subjects remained fasted until at least 4 hours post-dose. Moreover the subjects were in a semi-recumbent position and remained semi-recumbent until at least 4 hours post-dose.No fluids were allowed from 1 hour before dosing until 2 hours post-dose. Water was provided ad libitum at all other times.~From Day 5 to Day 12, subjects received givinostat 50 mg as oral suspension, twice a day, in the morning and in the evening."

Trial Locations (1)

153

Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires, Porto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Italfarmaco

INDUSTRY